<DOC>
	<DOCNO>NCT00944892</DOCNO>
	<brief_summary>This double-blind , prospective , randomized study patient randomize 1 4 treatment arm ( 3 active 1 placebo ) . Each patient receive two dos active medication placebo , study drug administer intravenously ( IV ) . The primary goal study assess safety tolerability repeat administration REGN475 compare placebo patient osteoarthritis ( OA ) knee .</brief_summary>
	<brief_title>A Study Safety Efficacy REGN475 ( SAR164877 ) Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Men woman ≥ 40 ≤ 75 year age . 2 . Diagnosis OA knee accord American College Rheumatology ( ACR ) criterion , experience moderate severe pain index knee least 3 month prior screen visit . 3 . KellgrenLawrence grade 23 radiographic severity index knee within 6 month prior Screening . 1 . Significant concomitant illness include , limited , cardiac , renal , neurological , endocrinological , metabolic lymphatic disease would adversely affect patient 's participation study . 2 . Patients joint replacement affect knee . 3 . Patients peripheral neuropathy due reason .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>